Brian Behnke
Rheumatology · Rancho Mirage, CANPI 1033679600
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations.
Across 81 payments — averaging $32.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$335
- AstraZeneca$240
- Amgen$171
- Boehringer Ingelheim$166
- Johnson & Johnson$165
- Sobi, Inc$152
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,43793%
- Education$1787%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 4 | $335 |
| AstraZeneca | 11 | $240 |
| Amgen | 8 | $171 |
| Boehringer Ingelheim | 3 | $166 |
| Johnson & Johnson | 5 | $165 |
| Sobi, Inc | 3 | $152 |
| UCB, Inc. | 6 | $137 |
| AbbVie | 5 | $131 |
| Novo Nordisk | 1 | $119 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Stemline Therapeutics Inc. | 2 | $78 |
| Daiichi Sankyo Inc. | 3 | $76 |
| Merck | 2 | $57 |
| GSK | 2 | $56 |
| Fresenius Kabi USA, LLC | 3 | $55 |
| Radius Health, Inc. | 2 | $53 |
| Iovance Biotherapeutics, Inc. | 2 | $48 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| Karyopharm Therapeutics Inc. | 1 | $34 |
| Spectrum Pharmaceuticals Inc. | 1 | $34 |
| Genmab U.S., Inc. | 1 | $33 |
| Servier Pharmaceuticals LLC | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Rigel Pharmaceuticals, Inc. | 1 | $28 |
| Legend Biotech USA Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $27 |
| Incyte Corporation | 1 | $27 |
| Puma Biotechnology, Inc. | 1 | $26 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| AVEO Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,615 in reported general payments places this provider in the 55th percentile of 808 rheumatology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MethotrexateMethotrexate Sodium | 19 | $417 |
| Hydroxychloroquine Sulfate | 18 | $402 |
| Leflunomide | 13 | $300 |
| Alendronate Sodium | 24 | $271 |
| Prednisone | 39 | $227 |
| Gabapentin | 14 | $205 |
| Tizanidine Hcl | 13 | $177 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Rancho Mirage
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.